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Background: Candida glabrata causes significant medical problems in immunocompromised patients. Many strains
of this yeast are intrinsically resistant to azole antifungal agents, and treatment is problematic, leading to high
morbidity and mortality rates in immunosuppressed individuals. The primary goal of this study was to investigate
the genes involved in the drug resistance of clinical isolates of C. glabrata.
Methods: The clinical isolates of C. glabrata were collected in an epidemiological survey of candidal infection in
immunocompromised patients and consisted of four fluconazole and itraconazole resistant isolates, two fluconazole
and itraconazole sensitive isolates, and C. glabrata CBS 138 as reference strain. Antifungal susceptibility patterns of
the organisms were determined beforehand by the Clinical and Laboratory Standards Institute (CLSI). The potential
gene(s) implicated in antifungal resistance were investigated using complementary DNA- Amplified Fragment
Length Polymorphism (cDNA-AFLP). Semi-quantitative RT-PCR was carried out to evaluate the expression of gene(s)
in resistant isolates as compared to sensitive and reference strains.
Results and conclusions: The aldo-keto-reductase superfamily (AKR gene) was upregulated in the resistant clinical
isolates as assessed by cDNA-AFLP. Semi-quantitative RT-PCR revealed AKR mRNA expression approximately twice
that seen in the sensitive isolates. Overexpression of the AKR gene was associated with increased fluconazole and
itraconazole resistance in C. glabrata. The data suggest that upregulation of the AKR gene might give a new insight
into the mechanism of azole resistance.
Keywords: Azole, Aldo-keto-reductase, cDNA-AFLP, Candida glabrata, Semi-quantitative RT-PCRBackground
The incidence of fungal infections has increased over the
past two decades. Opportunistic fungal infections occur in
immunocompromised hosts [1], particularly among
patients infected with human immunodeficiency virus
(HIV), individuals receiving immunosuppressive therapy
for organ or stem cell transplantation, and cancer patients
[2]. Candida glabrata has emerged as a common fungal
pathogen in many countries and is often reported as the
second most prevalent species after C. albicans [3].
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reproduction in any medium, provided the orfluconazole [4,5] and is less sensitive to it than C. albicans,
C. parapsilosis, or C. tropicalis. Studies have shown that
mechanisms of azole resistance in C. glabrata are often
associated with the upregulation of the genes CgCDR1 (C.
glabrata Candida drug resistance), CgCDR2 (formerly
PDH1) [6,7], and CgSNQ2 (C. glabrata sensitivity to
4-nitroquinoline N-oxide) which encode proteins belonging
to ATP binding cassette (ABC) transporters [8]. CgSNQ2
was controlled by CgPDR1 (C. glabrata pleiotropic drug
resistance 1) [9]. A further azole resistance mechanism
in C. glabrata has been shown to be the mutation or
overexpression of the ERG11 gene (CgERG11) that
encodes cytochrome P-450 lanostrol 14-α demethylase, the
azole target enzyme, and increases CYP51 (the ERG11
orthologue) activity, enhancing azole resistance [10].l Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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fluconazole resistance of Candida krusei and Candida
albicans [6,11,12]. The molecular mechanisms in the
resistant strains of C. glabrata are not completely under-
stood. In this study, antifungal resistance mechanisms were
investigated using cDNA-AFLP, a genome-wide expression
analysis method that does not require prior sequence
knowledge of the genes [13]. This technology is an ideal
alternative to microarrays [14].
Materials and methods
Yeast isolates
Four fluconazole and itraconazole resistant isolates, two
fluconazole and itraconazole sensitive isolates, and one
reference strain of C. glabrata were used. The isolates of
C. glabrata were obtained from clinical samples collected
in an epidemiological survey of candidal infections in im-
munocompromised patients conducted at the Department
of Medical Mycology and Parasitology, Tehran. The clinical
isolates were recovered from oropharynx of patients. The
reference C. glabrata strain, CBS 138, was provided by
Professor Koichi Makimura, Teikyo University Institute of
Medical Mycology-Tokyo, Japan (Table 1). The clinical
isolates were identified using standard mycological
methods, including assimilation patterns.
Culture conditions and drug susceptibility testing
The isolates and reference strain were cultured on a yeast
extract peptone-glucose (YEPD) agar plate containing
5 g/l yeast extract (Baltimore Biological Laboratory, USA),
10 g/l peptone (Merck, Germany), 20 g/l glucose (Merck,
Germany), 0.5 g/l chloramphenicol; and 20 g/l agar (Biolife,
Italy) incubated at 37°C for 72 h. A single colony of each
isolates and reference strain was selected and subcultured
in YEPD broth for 24 h at 37°C. Resistant isolate No. 51
was cultured in YEPD broth with fluconazole (128 μg/ml)
for 48 h at 37°C. Susceptibility to fluconazole and itracona-
zole drugs was determined by microdilution according to
the criteria for Clinical and Laboratory Standards Institute
(CLSI) M27–A2 (formerly NCCLS) [15,16].Table 1 Number of isolates, site of isolation and azole








94 Oropharynx 0.25 0.5
45 Oropharynx 0.5 0.25
51 Oropharynx 64 2
153 Oropharynx 64 4
137 Oropharynx 64 2
219 Oropharynx 64 2RNA extraction
Total RNA was extracted from the exponential phase using
the RNeasy Protect Mini Kit (Qiagen, Germany). For
mechanical disruption, the yeast cells were sonicated with
acid-washed glass beads (0.45–0.52 mm diameter). The
released RNA was treated through an RNase-free DNase
step (Qiagen, Germany) and quantity and quality of RNA
was measured with the Nanodrop 1000 spectrophotometer
(Thermo Scientific, USA).cDNA-AFLP
Complementary DNA Amplified Fragment Length Poly-
morphism (cDNA-AFLP) was conducted with minor modi-
fications. For complementary DNA (cDNA) synthesis, 6 μg
of total RNA from each isolate was heated at 65°C for
10 min, followed by cooling on ice. A master mixture
contained 7.5 μl of 5X reverse transcriptase (RT) buffer
comprising Tris–HCl (pH 8.3 at 25°C) (Fermentas,
Canada); 1 μl Oligo dT (20 pmol/μl); all four dNTPs
(10 mM) 1.5 μl; Ribolock (20 U) 1.5 μl (Fermentas,
Canada); and DEPC treated water. Two hundred units
of Moloney Murine Leukemia Virus (M-MuLV) reverse
transcriptase enzyme (Fermentas) were added. The RT
temperature was 42°C for 60 min and 70°C for 10 min.
cDNA was checked with the reference gene URA3
(orotidine-5’-phosphate decarboxylase) with the following
PCR conditions: 5 min at 94°C; 30 cycles of 30 s at 94°C,
30 s at 55°C, 45 s at 72 °C, and 7 min at 72°C. Primers were
designed with the NCBI primer–BLAST (Basic Local
Alignment Search Tool) program http://www.ncbi.nih.gov/
primer-BLAST (Table 2). DNA polymerase I (Fermentas,
Canada) was used for second strand cDNA synthesis at
16°C for 3 h and was precipitated with ethanol. The quality
of dscDNA was evaluated with the Nanodrop 1000
spectrophotometer (Thermo Scientific). Two micrograms
dscDNA were digested with the MboI restriction enzyme
(Fermentas) for 4 h at 37°C, and the enzyme was inacti-
vated at 80°C for 20 min. Eight μg of ADMbo1 and 4 μg of
adMbo1 cDNA-AFLP adaptors (Table 3) were ligated to
MboI digested dscDNA fragments by T4 DNA Ligase
(Takara Bio Inc. Japan) conducted at 1 min at 50°C,
decreasing to 10°C over the course of 1 h (1°C per 90 s). T4
DNA ligase was added, and the mixture was incubated at
16°C for 16 h. The pre-amplification was performed with
the PreAmp adaptor as primer with the following PCR
conditions: 5 min of denaturation at 94°C; 30 cycles of 94°C
for 30 s, 55°C for 30 s, 72°C for 30 s; and a final extension
at 72°C for 5 min. The sensitive adaptors used in sensitive
amplification were designed with one selective base at the
3′end (Table 3). Ten PCRs were performed utilizing all
sensitive adaptor combinations, and the PCR products
were separated by 8% non-denaturated poly acrylamide
gel electrophoresis (PAGE) and stained with silver nitrate.
Table 2 Primers used in this study
Gene Primer Sequence Gene location (5′-3′) Product size (bp)
URA3 URA3 F GGGCTCTTTAGCTCATGGTG 432-451 173
URA3 R CAAGTGCATCGCCTTTATCA 604-585
AKR AKR F GGTCTCGGGCCTCGGCTACA 321-340 289
AKR R TGGGGCATACGCCTCGACCA 609-590
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were observed.Isolation, cloning, and sequencing of cDNA-AFLP
fragments
Selected bands were isolated from the PAGE and
re-amplified using appropriate sensitive adaptors. The
TDFs were cloned using a TA-cloning kit (Invitrogen,
USA) and the recombinant plasmids were screened using
M13 forward (−20) (5′-GTAAAACGACGGCCAG-3′)
and M13 reverse (5′-CAGGAAACAGCTATGAC-3′)
primers with the following PCR protocol: 30 cycles of 94°C
for 1 min, 55°C for 1 min; 72 C for 1 min; and 72°C for
7 min. PCR products were analyzed by agarose gel
electrophoresis . The recombinant plasmids containing
unknown DNA were sequenced by M13 forward (−20)
and M13 reverse primers. Some TDFs were verified with
direct sequencing (Macrogene, Korea). Sequence data were
analyzed in non-redundant nucleic and protein databases
BLAST (http://www.ncbi.nim.nih.gov/BLAST/).Semi-quantitative RT-PCR
Semi-quantitative RT-PCR was carried out to evaluate the
mRNA overexpression level of TDFs, which were identified
by cDNA-AFLP [17] using specifically designed primers
(Table 2). An equal amount (6 μg) of total RNA from each
of the clinical isolates and the CBS 138 reference strain was
used for first strand cDNA synthesis, and the expression
pattern in cDNA-AFLP was determined with the primers
on RNA of clinical isolates. The URA3 gene was used as
internal control and negative controls were prepared with
sterile water as template. The gel image was captured








S4Mbo1 AGCACTCTCCAGCCTCTCACCGCAGATCTThe band intensity was analyzed and quantified with gel
analysis software UVI (Roche, Germany).Results
Antifungal susceptibility
Susceptibility to fluconazole and itraconazole was deter-
mined by the broth microdilution method described in the
CLSI (document M27-A2). The minimum inhibitory
concentration (MIC) of fluconazole and itraconazole
obtained against clinical isolates of C. glabrata showed
four strains resistant to fluconazole (MIC 64 μg/ml) and
itraconazole (MIC 2–4 μg/ml), while two strains were
susceptible to fluconazole (MIC 0.25–0.50 μg/ml) and
itraconazole (MIC 0.25–0.50 μg/ml) (Table 1).cDNA-AFLP
The cDNA-AFLP products of clinical isolates and reference
strain
Fragments of cDNA-AFLP were observed on 8% non-
denaturing PAGE using silver staining. Over 100 TDFs
were produced using 10 primer combinations. Twenty
fragments were identified as differentially regulated. High
expression TDFs were observed in the resistant isolates,
with lower levels of cDNA-AFLP fragments detected in the
sensitive isolates. Ten TDFs ranging from 120 bp to
600 bp were isolated from the cDNA-AFLP profile and
identified by cloning and DNA sequencing (Table 4). A
differentially expressed TDF was produced at approxi-
mately 550 bp when using S3Mbo1 and S4Mbo1 as
sensitive primers (Figure 1). Sequencing showed that
the TDF was consistent with the gene associated with
aldo-keto-reductase (AKR gene: Gene ID: 2886902;
Gene Symbol: CAGL0C04543g; XM_445372.1). Other
clones contained two unknown function sequences
observed at about 320 bp and 360 bp using S2Mbo1/
S2Mbo1 and S2Mbo1/S3Mbo1 as sensitive primers,
respectively (Figure 2).Table 4 Sequences identified by cDNA-AFLP
Accession no. Size (bp) Identity
XM_445372.1 550 aldo-keto-reductase
XM_446417.1 320 unknown function
XM_444814.1 360 unknown function
Figure 1 Expression pattern of TDFs of cDNA-AFLP PAGE. Sensitive amplification of cDNA-AFLP on a PAGE from S3Mbo1/S4Mbo1 as primers.
The lanes numbered correspond to the clinical isolates presented in Table 1. The arrows point to a differentially expressed TDFs. M: Marker 50 bp;
* FLU: Fluconazole.
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To confirm AKR as a potential gene for azole resistance, a
semi-quantitative RT-PCR technique was performed on
the cDNAs from resistant and sensitive clinical isolates as
well as on the CBS 138 reference strain. Figure 3 repre-
sents the upregulation of AKR mRNA expression levels inFigure 2 Expression pattern of TDFs of cDNA-AFLP PAGE using
silver staining. Sensitive amplification of cDNA-AFLP on a PAGE
from primer combinations S2Mbo1/S2Mbo1 and S2Mbo1/S3Mbo1.
The lanes numbered correspond to the clinical isolates presented in
Table 1. The arrows point to differentially expressed TDFs. DNA
ladder; M: (100 bp) molecular weight marker. *FLU: Fluconazole.these samples. Semi-quantitative RT-PCR showed that
AKR mRNA expression was about twice that seen in the
sensitive isolates (Figure 4). AKR transcript level in the
resistant isolate treated with fluconazole was the same
as the one observed in the resistant clinical isolates
(data not shown).
Discussion
Candida glabrata, second only to C. albicans as an
infectious pathogen in candidiasis, contributes to an
average of 11% of candidal infections, varying from 7%
to 20% depending on geographic location [18]. In the
survey providing data for the present study of immuno-
compromised patients, C. glabrata accounted for about
15% of candidal infections. Twenty-five percent of the
isolates were resistant to fluconazole (Zaini et al.,
unpublished data). Although several genes may be
implicated in azole resistance, the molecular pathways
involved are not completely understood.
We report, for the first time using cDNA-AFLP, AKR
transcripts upregulated in resistant clinical isolates. The
AKR gene is not the first suggested to be involved in azole
resistance. Upregulation of CgCDR1 and CgCDR2 genes
associated with increased expression of the ABC trans-
porter has been well documented [19,20]. The PDR1 gene
is important in acquired azole resistance [21], and so-called
gain-of-function mutations of the CgPDR1 gene have been
shown to play an essential role in azole resistance by C.
glabrata [22-25]. These mutations indicate that many genes
are differentially regulated in azole resistant isolates as
compared to the wild type. Multiple genes (from 27–235)
Figure 3 Semi quantitative RT-PCR analysis of AKR gene mRNA expression. The lanes numbered correspond to the clinical isolates
presented in Table 1. N, negative control (water). URA3 gene (173 bp) was used as internal control.
Farahyar et al. DARU Journal of Pharmaceutical Sciences 2013, 21:1 Page 5 of 7
http://www.darujps.com/content/21/1/1show increased expression, and aldo-keto-reductase
(CAGL0C04543g: XM_445372.1) is upregulated (1.5 to
2-fold) [25]. The results of the present study also
demonstrated that AKR mRNA expression in azole
resistance reaches levels of about twice that found in
sensitive strains. The molecular mechanisms of azole
resistance in C. albicans are connected with overexpres-
sion of ATP-binding cassette (ABC) transporters or major
facilitator superfamily, and upregulation of these genes
can also be brought about by exposure to benomyl and
fluphenazine. In the presence of benomyl, some genes
belonging to the aldo-keto reductase family, such as IFD
genes, IPF5987, and GRP2, can be activated with the
oxido-reductase function [26].
The aldo-keto-reductase superfamily (AKR) comprises
several proteins with similar kinetic and structural proper-
ties and has been found in a wide range of phyla, including
both prokaryotes and eukaryotes [27]. AKRs catalyze the
reduction of aldehydes and ketones to their corresponding
alcohol products by reducing nicotinamide adenine
dinucleotide phosphate (NADPH) cofactor [28]. SeveralFigure 4 AKR gene showed increased expression level after normaliza
isolates of C. glabrata sensitive to fluconazole and itraconazole; 3 shows CBdrugs and pharmaceuticals are reactive carbonyls and
aldehydes or are converted to carbonyls during in vivo
metabolism. An important role of AKRs is in preventing
carbonyl toxicity [27]. The physiological roles of this
superfamily have been studied in the yeast Saccharomyces
cerevisiae, a simple eukaryote containing various AKR
genes that encode proteins similar in structure and function
to mammalian AKRs, including those of humans. The
physiological activity of yeast AKRs is largely unclear. Prior
studies have identified six open reading frames (YHR104W,
YOR120W, YDR368W, YBR149W, YJR096W, YDL124W)
in the S. cerevisiae genome that encode proteins with acti-
vity overlapping human aldose reductase [29]. YHR104W
and YDR368W are stress response proteins [30]. The
product of YOR120W is a galactose-inducible crystalline-
like yeast protein, and YBR149W encodes a dehydrogenase
that plays a role in the direction of arabinose oxidation
rather than reduction [31]. Numerous studies have demon-
strated that aldo-keto-reductases are active in stress
conditions. Another important role of the yeast AKR
genes is to protect against heat shock stress [32]. Intion with internal control (URA3). Samples 1 and 2 show clinical
S 138, and samples 4,5,6,7 are resistant clinical isolates.
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and transcriptional regulation [33]. AKR function has also
been reported in drug metabolism and detoxification of
pharmaceuticals, drugs, and xenobiotics in humans [27],
and it seems that the physiological roles of the AKR gene in
yeast are similar to those in humans. Our results suggest
upregulation of AKR gene is involved in the molecular
mechanism of drug resistance in C. glabrata.
Conclusion
Aldo-keto-reductases are important in intermediary
metabolism, detoxification, and stress conditions. The
AKR gene was highly expressed in azole resistant
C. glabrata, and may be associated with the biological
networks of drug resistance factors of C. glabrata. To the
best of our knowledge, this study is the first to report the
implication of AKR in azole resistance among C. glabrata
clinical isolates, using the cDNA-AFLP technique. Further
investigations are needed to clarify the role of this gene.
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